Immunisation of the travelling child

Travel Medicine and Infectious Disease

Volumn 5, Issue 6, 2007, Pages 349-364

  Giovanetti, Franco ^a  

^a Azienda Sanitaria Locale Alba Bra   (Italy)

Author keywords

Children; Immunisation; Travel

Indexed keywords

AMIKACIN; BCG VACCINE; CAPREOMYCIN; CHICKENPOX VACCINE; CHOLERA VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FSME IMMUN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOGLOBULIN; INACTIVATED VACCINE; INFLUENZA VACCINE; ISONIAZID; JAPANESE ENCEPHALITIS VACCINE; KANAMYCIN; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; MUTACOL; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; RIFAMPICIN; ROTAVIRUS VACCINE; TETANUS TOXOID; TICK BORNE ENCEPHALITIS VACCINE; TICOVAC; TWINRIX JUNIOR; TYPHERIX; TYPHOID VACCINE; UNCLASSIFIED DRUG; VACCINE; YELLOW FEVER VACCINE;

ANGIONEUROTIC EDEMA; ARTICLE; CHICKENPOX; CHILD HEALTH; CHOLERA; CLINICAL TRIAL; DIPHTHERIA; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; EMPORIATRICS; EPIDEMIC ENCEPHALITIS; FACE EDEMA; FAMILY; HEPATITIS A; HUMAN; IMMUNIZATION; INFECTION RISK; INFLUENZA; MEASLES; MUMPS; PERTUSSIS; POLIOMYELITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; RABIES; REPEATED DRUG DOSE; REVACCINATION; RISK ASSESSMENT; ROTAVIRUS; RUBELLA; SEROCONVERSION; SINGLE DRUG DOSE; STREPTOCOCCUS INFECTION; TETANUS; TICK BORNE ENCEPHALITIS; TRAVEL; TUBERCULOSIS; TYPHOID FEVER; UNSPECIFIED SIDE EFFECT; URTICARIA; VIRUS INFECTION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASE CONTROL; HUMANS; IMMUNIZATION; INFANT; INFANT, NEWBORN; TRAVEL; VACCINES;

EID: 35548959536     PISSN: 14778939     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmaid.2007.09.004     Document Type: Article

References (125)

1. Bacaner N., Stauffer B., Boulware D.R., Walker P.F., and Keystone J.S. Travel medicine considerations for North American immigrants visiting friends and relatives. JAMA 291 (2004) 2856-2864
2. Fair E., Murphy T.V., Golaz A., and Wharton M. Philosophic objection to vaccination as a risk for tetanus among children younger than 15 years. Pediatrics 109 (2002) E2
3. Giovanetti F., and Pellegrino A. A case of tetanus in a child whose parents refused immunisation-Piedmont Region, Italy, 2006. Euro Surveill 12 6 (2007) E070621.2. http://www.eurosurveillance.org/ew/2007/070621.asp#2 Available at: 〈http://www.eurosurveillance.org/ew/2007/070621.asp#2〉
4. Steffen R., and Connor B.A. Vaccines in travel health: from risk assessment to priorities. J Travel Med 12 (2005) 26-35
5. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(RR-15):1-48. Available at: 〈http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm〉.
6. Buttery J., La Vincente S., Andrews R., Kempe A., and Royle J. Adverse events following immunisation: desperately seeking surveillance. Lancet Infect Dis 6 (2006) 680-681
7. Committee on Infectious Diseases. Recommended immunization schedules for children and adolescents-United States, 2007. Pediatrics 119 (2007) 207-208
8. Bray J.P., Burt E.G., Potter E.V., Poon-King T., and Earle D.P. Epidemic diphtheria and skin infections in Trinidad. J Infect Dis 126 (1972) 34-40
9. Koopman J.S., and Campbell J. The role of cutaneous diphtheria infections in a diphtheria epidemic. J Infect Dis 131 (1975) 239-244
10. Galazka AM. The immunological basis for immunization series. Module 2: Diphtheria. WHO/EPI/GEN/98.13.1993. Geneva: World Health Organization; 1993. Available at: 〈http://www.who.int/vaccines-documents/DocsPDF-IBI-e/mod2_e.pdf〉.
11. CDC. Fatal respiratory diphtheria in a US traveler to Haiti-Pennsylvania, 2003. MMWR 2004;52:1285-6. Available at: 〈http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5253a3.htm〉.
12. De Benoist A.C., White J.M., Efstratiou A., Kelly C., Mann G., Nazareth B., et al. Imported cutaneous diphtheria, United Kingdom. Emerg Infect Dis 10 (2004) 511-513
13. Vitek C.R., and Wharton M. Diphtheria in the former Soviet Union: reemergence of a pandemic disease. Emerg Infect Dis 4 (1998) 539-550
14. Galazka AM. The immunological basis for immunisation series: Module 3: Tetanus. WHO/EPI/GEN/98.13.1993. Geneva: World Health Organization; 1993. Available at: 〈http://www.who.int/vaccines-documents/DocsPDF-IBI-e/mod3_e.pdf〉.
15. Stojanov S., Liese J., and Belohradsky B.H. Hospitalization and complications in children under 2 years of age with Bordetella pertussis infection. Infection (2000) 106-110
16. Heininger U., Kleemann W.J., Cherry J.D., and Sudden Infant Death Syndrome Study Group. A controlled study of the relationship between Bordetella pertussis infections and sudden unexpected deaths among German infants. Pediatrics 114 (2004) e9-e15
17. Jefferson T., Rudin M., and DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 21 (2003) 2003-2014
18. CDC. Progress toward interruption of wild poliovirus transmission-worldwide, January 2006-May 2007. MMWR 56 (2007) 682-685
19. Plotkin S.A., Murdin A., and Vidor E. Poliovirus vaccine-inactivated. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 3rd ed (1999), WD Saunders, Philadelphia 345-363
20. CDC. Poliomyelitis Prevention in the United States. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(RR05):1-22. Available at: 〈http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4905a1.htm〉.
21. World Health Organization. WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 81 (2006) 445-452. http://www.who.int/wer/2006/wer8147.pdf Available at: 〈http://www.who.int/wer/2006/wer8147.pdf〉
22. WHO. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec 82 (2007) 93-104. http://www.who.int/wer/2007/wer8212.pdf Available at: 〈http://www.who.int/wer/2007/wer8212.pdf〉
23. CDC. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR 54 (2005) 893-897. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5436a1.htm Available at: 〈http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5436a1.htm〉
24. Hausdorff W.P., Feikin D.R., and Klugman K.P. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5 (2005) 83-93
25. World Health Organization. Hepatitis B vaccines-WHO position paper. Wkly Epidemiol Rec 79 (2004) 255-263. http://www.who.int/immunization/wer7928HepB_July04_position_paper.pdf Available at: 〈http://www.who.int/immunization/wer7928HepB_July04_position_paper.pdf〉
26. CDC. Absence of transmission of the d9 measles virus-region of the Americas, November 2002-March 2003. MMWR 52 (2003) 228-229. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5211a6.htm Available at: 〈http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5211a6.htm〉
27. Boncompagni G., Incandela L., Bechini A., Giannini D., Cellini C., Trezzi M., et al. Measles outbreak in Grosseto, central Italy, 2006. Euro Surveill 11 8 (2006) E060803.4. http://www.eurosurveillance.org/ew/2006/060803.asp#4 Available at: 〈http://www.eurosurveillance.org/ew/2006/060803.asp#4〉
28. Filia A., Curtale F., Kreidl P., Morosetti G., Nicoletti L., Perrelli F., et al. Cluster of measles cases in the Roma/Sinti population, Italy, June-September 2006. Euro Surveill 11 10 (2006) E061012.2. http://www.eurosurveillance.org/ew/2006/061012.asp#2 Available at: 〈http://www.eurosurveillance.org/ew/2006/061012.asp#2〉
29. CDC. Progress in reducing global measles deaths, 1999-2004. MMWR 55 (2006) 247-249. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5509a8.htm Available at: 〈http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5509a8.htm〉
30. Santos N., and Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 15 (2005) 29-56
31. Gentsch J.R., Laird A.R., Bielfelt B., et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis 192 Suppl. 1 (2005) S146-S159
32. Grimwood K., and Buttery J.P. Clinical update: rotavirus gastroenteritis and its prevention. Lancet 370 (2007) 302-304
33. Vesikari T., Matson D.O., Dennehy P., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354 (2006) 23-33
34. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354 (2006) 11-22
35. Lopez A.S., Guris D., Zimmerman L., Gladden L., Moore T., Haselow D.T., et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?. Pediatrics 117 (2006) 1070-1077
36. Freedman D.O., and Leder K. Influenza: changing approaches to prevention and treatment in travellers. J Travel Med 12 (2005) 36-44
37. CDC. Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR 56 (2007) 1-54. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr56e629a1.htm Available at: 〈http://www.cdc.gov/mmwr/preview/mmwrhtml/rr56e629a1.htm〉
38. Jefferson T., Smith S., Demicheli V., Harnden A., Rivetti A., and Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet 365 (2005) 773-780
39. Poehling K.A., Edwards K.M., Weinberg G.A., Szilagyi P., Staat M.A., et al. The underrecognized burden of influenza in young children. N Engl J Med 355 (2006) 31-40
40. Wittlinger F., Steffen R., Watanabe H., et al. Risk of cholera among western and Japanese travelers. J Travel Med 2 (1995) 154-158
41. WHO. Cholera, 2006. Wkly Epidemiol Rec 82 (2007) 273-284. http://www.who.int/wer/2007/wer8231.pdf Available at: 〈http://www.who.int/wer/2007/wer8231.pdf〉
42. WHO. Cholera, 2004. Wkly Epidemiol Rec 80 (2005) 261-268. http://www.who.int/wer/2005/wer8031.pdf Available at: 〈http://www.who.int/wer/2005/wer8031.pdf〉
43. Thiem V.D., Deen J.L., von Seidlein L., Canh do G., Anh D.D., Park J.K., et al. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine 24 (2006) 4297-4303
44. Lucas M.E., Deen J.L., von Seidlein L., Wang X.Y., Ampuero J., Puri M., et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 352 (2005) 757-767
45. Calain P., Chaine J.P., Johnson E., Hawley M.L., O'Leary M.J., Oshitani H., et al. Can oral cholera vaccination play a role in controlling a cholera outbreak?. Vaccine 22 (2004) 2444-2451
46. Nair G.B., and Albert M.J. Vibrio cholerae O139 Bengal-10 years on. Rev Med Microbiol 16 4 (2005) 135-143
47. Dallas W.S., and Falkow S. Amino acid sequence homology between cholera toxin and Escherichia coli heat-labile toxin. Nature 288 (1980) 499-501
48. Steffen R., Castelli F., Dieter Nothdurft H., Rombo L., and Zuckerman J.N. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. J Travel Med 12 (2005) 102-107
49. EMEA. Dukoral. Scientific discussion. Human Medicines EMEA 2005. Available at: 〈www.emea.eu.int/humandocs/PDFs/EPAR/dukoral/408903en6.pdf〉
50. Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on oral cholera vaccination. Canada communicable disease report vol. 24 (ACS-5), 1 December 1998. Available at: 〈http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/98vol24/24sup/acs5.html#catmat〉.
51. Steffen R., Kane M.A., Shapiro C.N., et al. Epidemiology and prevention of hepatitis A in travelers. JAMA 272 (1994) 885-889
52. Mutsch M., Spicher V.M., Gut C., and Steffen R. Hepatitis A virus infections in travelers, 1988-2004. Clin Infect Dis 42 (2006) 490-497
53. Bonanni P., Franzin A., Staderini C., Pitta M., Garofalo G., Cecconi R., et al. Vaccination against hepatitis A during outbreaks starting in schools: what can we learn from experiences in central Italy?. Vaccine 23 (2005) 2176-2180
54. Gervelmeyer A., Nielsen M.S., Frey L.C., Sckerl H., Damberg E., and Molbak K. An outbreak of hepatitis A among children and adults in Denmark, August 2002 to February 2003. Epidemiol Infect 30 (2005) 1-7
55. Frank C., Walter J., Muehlen M., Jansen A., van Treeck U., Hauri A., et al. Large outbreak of hepatitis A in tourists staying at a hotel in Hurghada, Egypt, 2004-orange juice implicated. Euro Surveill 10 6 (2005) E050609.2. http://www.eurosurveillance.org/ew/2005/050609.asp#2 Available at: 〈http://www.eurosurveillance.org/ew/2005/050609.asp#2〉
56. CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 55 RR07 (2006) 1-23. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5507a1.htm Available at: 〈http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5507a1.htm〉
57. Usonis V., Bakasenas V., Valentelis R., Katiliene G., Vidzeniene D., and Herzog C. Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). Vaccine 21 (2003) 4588-4592
58. Riedemann S., Reinhardt G., Ibarra H., and Frosner G.G. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in healthy toddlers and children in Chile. Acta Paediatr 93 (2004) 412-414
59. Bell B.P., Negus S., Fiore A.E., Plotnik J., Dhotre K.B., Williams J., et al. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr Infect Dis J 26 (2007) 116-122
60. Dagan R., Amir J., Mijalovsky A., Kalmanovitch I., Bar-Yochai A., Thoelen S., et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 19 (2000) 1045-1052
61. Van Herck K., and Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 63 (2001) 1-7
62. Van Damme P., Banatvala J., Fay O., Iwarson S., McMahon B., Van Herck K., et al. Hepatitis A booster vaccination: is there a need?. Lancet 362 (2003) 1065-1071
63. Zuckerman J.N., Connor B.A., and von Sonnenburg F. Hepatitis A and B booster recommendations: implications for travelers. Clin Infect Dis 41 (2005) 1020-1026
64. Sagliocca L., Amoroso P., Stroffolini T., Adamo B., Tosti M.E., Lettieri G., et al. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial. Lancet 353 (1999) 1136-1139
65. Troisi C.L., Hollinger F.B., Krause D.S., and Pickering L.K. Immunization of seronegative infants with hepatitis A vaccine (HAVRIX; SKB): a comparative study of two dosing schedules. Vaccine 15 (1997) 1613-1617
66. In: Pickering L.K., Baker C.J., Long S.S., and McMillan J.A. (Eds). Red Book: 2006 report of the committee on infectious diseases. 27th ed (2006), American Academy of Pediatrics, Elk Grove Village, IL
67. Immunoglobulin handbook. Indications and dosage for normal and specific immunoglobulin preparations issued by the Health Protection Agency. Revised January 2007. Available at: 〈http://www.hpa.org.uk/infections/topics_az/immunoglobulin/pdfs/ig_handbookJan2007.pdf〉.
68. CDC. Inactivated Japanese encephalitis virus vaccine. Recommendations of the advisory committee on immunization practices (ACIP). MMWR 1993;42(No. RR-1). Available at: 〈http://iier.isciii.es/mmwr/preview/mmwrhtml/00020599.htm〉.
69. WHO. Japanese encephalitis vaccines. Wkly Epidemiol Rec 81 (2006) 331-340. http://www.who.int/wer/2006/wer8134_35.pdf Available at: 〈http://www.who.int/wer/2006/wer8134_35.pdf〉
70. Schiøler K., Samuel M., and Wai K. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst Rev 3 (2007) CD004263
71. Arguin PM, Kozarsky PE, Reed C, editors. Yellow book: health information for international travel, 2008 US Department of Health and Human Services: 2007. Available at: 〈http://wwwn.cdc.gov/travel/contentYellowBook.aspx〉.
72. WHO. Global Advisory Committee on Vaccine Safety, 9-10 June 2005. Wkly Epidemiol Rec 80 (2005) 242-247. http://www.who.int/wer/2005/wer8028.pdf Available at: 〈http://www.who.int/wer/2005/wer8028.pdf〉
73. Takahashi H., Pool V., Tsai T.F., and Chen R.T. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group. Vaccine 18 (2000) 2963-2969
74. WHO. Meningococcal meningitis. Wkly Epidemiol Rec 78 (2003) 285-296. http://www.who.int/wer/2003/en/wer7833.pdf Available at: 〈http://www.who.int/wer/2003/en/wer7833.pdf〉
75. Lingappa J.R., Al-Rabeah A.M., Hajjeh R., Mustafa T., Fatani A., Al-Bassam T., et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis 9 (2003) 665-671
76. An Advisory Committee Statement (ACS). Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on meningococcal vaccination for travellers. Can Commun Dis Rep 25 (1999) 1-12. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/99pdf/acs25-5.pdf Available at: 〈http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/99pdf/acs25-5.pdf〉
77. European Union Invasive Bacterial Infections Surveillance Network. Invasive Neisseria meningitidis in Europe 2003/2004. Available at: 〈http://www.euibis.org/reports.htm〉.
78. CDC. Prevention and Control of Meningococcal Disease. MMWR 54 RR-7 (2005). http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5407a1.htm Available at: 〈http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5407a1.htm〉
79. In: Salisbury D., Ramsay M., and Noakes K. (Eds). Immunisation against infectious disease: the Green Book. 3rd ed (2006), Department of Health. http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Greenbook/index.htm Available at: 〈http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Greenbook/index.htm〉
80. Goldblatt D. Recent developments in bacterial conjugate vaccines. J Med Microbiol 47 (1998) 563-567
81. Offit P.A., and Peter G. Meningococcal conjugate vaccine in the UK: an update. Lancet 364 (2004) 309-310
82. Public Health Agency of Canada. Canadian immunization guide 7th edition-2006. Available at: 〈http://www.phac-aspc.gc.ca/publicat/cig-gci/index.html〉.
83. CDC. Revised recommendations of the Advisory Committee on immunization practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR 56 (2007) 794-795. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5631a3.htm Available at: 〈http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5631a3.htm〉
84. CDC. Update: Guillain-Barré Syndrome among recipients of Menactra® meningococcal conjugate vaccine-United States, June 2005-September 2006. MMWR 55 (2006) 1120-1124. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5541a2.htm Available at: 〈http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5541a2.htm〉
85. WHO. Rabies vaccines. Wkly Epidemiol Rec 77 (2002) 109-120. http://www.who.int/immunization/wer7714rabies_Apr02_position_paper.pdf Available at: 〈http://www.who.int/immunization/wer7714rabies_Apr02_position_paper.pdf〉
86. Warrell M. Rabies Encephalitis and its prophylaxis. Pract Neurol 1 (2001) 14-29
87. Briggs D.J. Rabies vaccination: protecting vulnerable travelers. Infect Med 19 (2002) 561-565
88. Sriaroon C., Sriaroon P., Daviratanasilpa S., Khawplod P., and Wilde H. Retrospective: animal attacks and rabies exposures in Thai children. Travel Med Infect Dis 4 (2006) 270-274
89. Siddiqui A., Usmani R.I., Anwer S., and Afsar S. Guillain-Barre syndrome occurring after rabies vaccination. J Pak Med Assoc 55 (2005) 87-88
90. Wilde H., Briggs D.J., Meslin F.X., Hemachudha T., and Sitprija V. Rabies update for travel medicine advisors. Clin Infect Dis 37 (2003) 96-100
91. Lang J., Duong G.H., Nguyen V.G., Le T.T., Nguyen C.V., Kesmedjian V., et al. Randomised feasibility trial of pre-exposure rabies vaccination with DTP-IPV in infants. Lancet 349 (1997) 1663-1665
92. Lang J., Hoa D.Q., Gioi N.V., Vien N.C., Nguyen C.V., Rouyrre N., et al. Immunogenicity and safety of low-dose intradermal rabies vaccination given during an Expanded Programme on immunization session in Viet Nam: results of a comparative randomized trial. Trans R Soc Trop Med Hyg 93 (1999) 208-213
93. Pengsaa K, Limkittikul K, Ariyasriwatana C, Chanthavich P, Attanath P, Malerczyk C, Sabchareon A. Immunogenicity and safety of pre-exposure Im and Id regimens of purified chick embryo cell rabies vaccine administered concomitantly with Japanese Encephalitis vaccine in toddlers. Abstract. 2nd Asian Congress of pediatric infectious diseases 2-4 September 2004, Kota Kinabalu, Malaysia.
94. Kunze U., and the ISW T.B.E. Tick-borne encephalitis: from epidemiology to vaccination recommendations in 2007. New issues-best practices. Wien Med Wochenschr 157 (2007) 228-232
95. Süss J. Epidemiology and ecology of TBE relevant to the production of effective vaccines. Vaccine 21 Suppl. 1 (2003) S19-S35
96. Haglund M., and Guenther G. Tick borne encephalitis-pathogenesis, clinical course and long term follow up. Vaccine 21 Suppl. 1 (2003) S11-S18
97. Rendi-Wagner P., Kundi M., Zent O., Banzhoff A., Jaehnig P., Stemberger R., et al. Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation. Vaccine 23 (2004) 427-434
98. Hayasaka D., Goto A., Yoshii K., et al. Evaluation of European tick-borne encephalitis virus vaccine against recent Siberian and far-eastern subtype strains. Vaccine 19 (2001) 4774-4779
99. Leonova G.N., Ternovoi V.A., Pavlenko E.V., Maistrovskaya O.S., Protopopova E.V., and Loktev V.B. Evaluation of vaccine Encepur Adult for induction of human neutralizing antibodies against recent Far Eastern subtype strains of tick-borne encephalitis virus. Vaccine 25 (2007) 895-901
100. Schöndorf I., Beran J., Cizkova D., Lesna V., Banzhoff A., and Zent O. Tick-borne encephalitis (TBE) vaccination: applying the most suitable vaccination schedule. Vaccine 25 (2007) 1470-1475
101. Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on tick-borne encephalitis. Can Commun Dis Rep 32 (2006) 1-20. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/06pdf/acs-32-03.pdf Available at: 〈http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/06pdf/acs-32-03.pdf〉
102. Rendi-Wagner P. Risk and prevention of tick-borne encephalitis in travelers. J Travel Med 11 (2004) 307-312
103. Zent O., Plentz A., Schwarz T.F., et al. TBE booster immunization according to the rapid immunization schedule: are 3-year booster intervals really necessary?. Vaccine 23 (2004) 312-315
104. WHO. Global tuberculosis control: surveillance, planning, financing: WHO report 2007. World Health Organization Geneva: World Health Organization; 2007. Available at: 〈http://www.who.int/tb/publications/global_report/en/〉.
105. Cobelens F., van Deutekom H., Draayer-Jansen I., Schepp-Beelen A., van Gerven P., van Kessel R., et al. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet 356 (2000) 461-465
106. Johnston V.J., and Grant A.D. Tuberculosis in travellers. Travel Med Infect Dis 1 (2003) 205-212
107. Lobato M.N., and Hopewell P.C. Mycobacterium tuberculosis infection after travel to or contact with visitors from countries with a high prevalence of tuberculosis. Am J Respir Crit Care Med 158 (1998) 1871-1875
108. Colditz G.A., Brewer T.F., Berkey C.S., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271 (1994) 698-702
109. Rodrigues L.C., Diwan V.K., and Wheeler J.G. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 22 (1993) 1154-1158
110. WHO. International travel and health. Geneva: WHO; 2007. Available at: 〈http://www.who.int/ith/en/〉.
111. CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 49 (2000) 1-51
112. Rose D.N., Schecter C.B., and Adler J.J. Interpretation of the tuberculin skin test. J Gen Intern Med 10 (1995) 635-642
113. Ekdahl K., de Jong B., and Andersson Y. Risk of travel-associated typhoid and paratyphoid fevers in various regions. J Travel Med 12 (2005) 197-204
114. Steinberg E.B., Bishop R., Haber P., Dempsey A.F., Hoekstra R.M., et al. Typhoid fever in travelers: who should be targeted for prevention?. Clin Infect Dis 39 (2004) 186-191
115. Connor B.A., and Schwartz E. Typhoid and paratyphoid fever in travellers. Lancet Infect Dis 5 (2005) 623-628
116. Ackers M.L., Puhr N.D., Tauxe R.V., and Mintz E.D. Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise. JAMA 283 (2000) 2668-2673
117. Meltzer, et al. Enteric fever in Israeli travelers: a nationwide study. J Travel Med 12 (2005) 275-281
118. Guzman C.A., Borsutzkya S., Griot-Wenk M., Metcalfe I.C., Pearman P., Collioud A., et al. Vaccines against typhoid fever. Vaccine 24 (2006) 3804-3811
119. WHO. Yellow fever. Fact sheet no. 100. Revised December 2001. Available at: 〈http://www.who.int/mediacentre/factsheets/fs100/en/〉.
120. CDC. Fatal yellow fever in a traveller returning from Amazonas, Brazil, 2002. MMWR 51 (2002) 324-325. http://www.cdc.gov/mmwr/PDF/wk/mm5115.pdf Available at: 〈http://www.cdc.gov/mmwr/PDF/wk/mm5115.pdf〉
121. Monath T.P. Yellow fever: an update. Lancet Infect Dis 1 (2001) 11-20
122. Niedrig M., Lademann M., Emmerich P., and Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 4 (1999) 867-871
123. WHO. Global Advisory Committee on Vaccine Safety, 3-4 December 2003. Yellow fever vaccine safety. Wkly Epidemiol Rec 79 (2004) 13-24. http://www.who.int/entity/wer/2004/wer7903.pdf Available at: 〈http://www.who.int/entity/wer/2004/wer7903.pdf〉
124. McMahon A.W., Eidex R.B., Marfin A.A., Russell M., Sejvar J.J., Markoff L., et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 25 (2007) 1727-1734
125. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the yellow fever 17D vaccine. Vaccine 22 (2004) 2103-2105